Wounds
3
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
ConvaTecNJ - Bridgewater
1 program1
Engenex™ pump and Bio-Dome™ Wound DressingPhase 41 trial
Active Trials
AP
Amryt PharmaUK - London
2 programs2
Oleogel-S10, non-adhesive wound dressingPhase 31 trial
Oleogel-S10, non-adhesive wound dressingPhase 31 trial
Active Trials
Carbon BiosciencesMA - Waltham
1 programhydrophilic-based dressingN/A1 trial
Active Trials
NCT01921725Completed
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
ConvaTecEngenex™ pump and Bio-Dome™ Wound Dressing
Amryt PharmaOleogel-S10, non-adhesive wound dressing
Amryt PharmaOleogel-S10, non-adhesive wound dressing
KerecisKerecis Fish Skin Graft
Carbon Bioscienceshydrophilic-based dressing
OrganogenesisVCT-01
Clinical Trials (6)
Total enrollment: 219 patients across 6 trials
Negative Pressure Wound Therapy With the Engenex™-Pump and Bio-Dome™ Dressing, an Evaluation
Start: Feb 2010Est. completion: Sep 2010
Phase 4Completed
Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Start: Mar 2013Est. completion: Sep 2014112 patients
Phase 3Completed
Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
Start: Aug 2012Est. completion: Sep 2014107 patients
Phase 3Completed
Kerecis Real-World Fish Skin Graft Registry
Start: Aug 2024Est. completion: Jun 2027
N/AEnrolling By Invitation
The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing
Start: May 2013
N/ACompleted
Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds
Start: Jun 2011Est. completion: Sep 2012
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space